gefitinib has been researched along with Oropharyngeal Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
Bakanauskas, VJ; Bernhard, EJ; Cerniglia, GJ; Feldman, MD; Goldsmith, JD; Gupta, AK; Machtay, M; McKenna, WG; Mick, R; Muschel, RJ; Rosenthal, DI; Weber, CN; Weber, RS | 1 |
1 review(s) available for gefitinib and Oropharyngeal Neoplasms
Article | Year |
---|---|
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
1 trial(s) available for gefitinib and Oropharyngeal Neoplasms
Article | Year |
---|---|
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Chromones; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; ras Proteins; Signal Transduction | 2002 |